Expression of the c-mpl proto-oncogene in human hematologic malignancies
| Autor: | Vincent Ribrag, Michèle Souyri, F Viguie, L Cocault, François Dreyfus, Sylvie Gisselbrecht, J. Melle, Isabelle Vigon |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Acute myeloblastic leukemia Lymphoma Hematopoietic growth factor Immunology Gene Expression Receptors Cell Surface Biochemistry Proto-Oncogene Mas Receptor tyrosine kinase Proto-Oncogene Proteins Proto-Oncogenes medicine Humans Northern blot RNA Messenger RNA Neoplasm Receptors Cytokine Receptors Immunologic Receptor Child Aged Leukemia Myeloproliferative Disorders Oncogene biology Myelodysplastic syndromes Gene Amplification Cell Biology Hematology Middle Aged medicine.disease Prognosis Neoplasm Proteins Myelodysplastic Syndromes Acute Disease biology.protein Female Cytokine receptor Receptors Thrombopoietin |
| Zdroj: | Blood. 82(3) |
| ISSN: | 0006-4971 |
| Popis: | Similar to two other hematopoietic growth factor receptors, the c-fms (macrophage colony-stimulating factor receptor) and the c-kit genes, c- mpl has been discovered through the study of oncogenic retroviruses. Unlike c-fms and c-kit, which both belong to a subgroup of tyrosine kinase receptors, the c-mpl proto-oncogene encodes a new member of the cytokine receptor superfamily. We have studied the expression of c-mpl in a series of 105 patients with hematologic malignancies using Northern blot analysis. The levels of c-mpl transcripts in lymphoid malignancies and in chronic myeloproliferative disorders were not significantly different from those found in normal bone marrow cells, in which c-mpl was barely detectable. In contrast, c-mpl expression was increased in 26 of 51 patients with acute myeloblastic leukemia (AML) and in 5 of 16 patients with myelodysplastic syndromes. Amplification of the c-mpl gene was detected in genomic DNA of one M4 AML patient. There was no significant correlation between c-mpl expression and the French-American-British classification of AML. Patients with high c-mpl expression appeared to belong to a subgroup of AML with a low rate of complete remission and a poor prognosis, including secondary leukemia and AML with unfavorable cytogenetic abnormalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|